Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Senile Cardiac Amyloidosis Clear all
Active, not recruiting Phase 4 Interventional

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

NCT05489523
View directory record Official record
Conditions
Transthyretin Cardiac Amyloidosis
Interventions
Tafamidis 61 MG
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Beverly Hills, California • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Early Phase 1 Interventional

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

NCT04899180
View directory record Official record
Conditions
Aortic Stenosis, Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions
99mTc-PYP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
75 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting No phase listed Observational

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

NCT06978660
View directory record Official record
Conditions
Transthyretin Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
Idoven 1903 S.L.
Industry
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting No phase listed Observational

Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)

NCT05139797
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
EchoNet-LVH screening for cardiac amyloidosis
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Not applicable Interventional Results available

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

NCT04421040
View directory record Official record
Conditions
TTR Cardiac Amyloidosis
Interventions
Biotronik Biomonitor 3 implant of device, Biotronik Biomonitor 3 explant of device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

NCT01855360
View directory record Official record
Conditions
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions
Tauroursodeoxycholic Acid and Doxycycline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting Not applicable Interventional

Exercise Training in Transthyretin Cardiac Amyloidosis

NCT05797857
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions
Exercise Training
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting No phase listed Observational

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

NCT05489549
View directory record Official record
Conditions
Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Transthyretin Gene Mutation
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 80 Years
Enrollment
500 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed No phase listed Observational Results available

Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

NCT03812172
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
99mTc-PYP or 99m Tc-HDP
Drug
Lead sponsor
Mathew S. Maurer, MD
Other
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Early Phase 1 Interventional

PET/MRI Evaluation of Cardiac Amyloid

NCT03119558
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
18F-Florbetaben (Neuraceq®) PET/MRI
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting Not applicable Interventional

Elevated Rate Pacing of Cardiac Amyloidosis

NCT07583823
View directory record Official record
Conditions
Cardiac Amyloidosis, Pacemaker
Interventions
Pacemaker Rate
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Phase 3 Interventional

REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

NCT06788535
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
I-124 evuzamitide
Drug
Lead sponsor
Sharmila Dorbala
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Recruiting No phase listed Observational

A Study Of MCG In Cardiac Amyloidosis

NCT07218705
View directory record Official record
Conditions
Amyloidosis
Interventions
SandboxAQ CardiAQ Magnetocardiography
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 21, 2026, 7:49 AM EDT
Enrolling by invitation Phase 2 Interventional

124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

NCT06907849
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
Interventions
124I-evuzamitide
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Not applicable Interventional

Penn Biobank Return of Research Results Program

NCT04242667
View directory record Official record
Conditions
Cancer, Cardiovascular Diseases, Hereditary Cancer, Hereditary Cardiac Amyloidosis
Interventions
e-Health (web-based) disclosure portal, Provider mediated disclosure
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 21, 2026, 7:49 AM EDT
Terminated Phase 4 Interventional Results available

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

NCT03333551
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005
View directory record Official record
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 21, 2026, 7:49 AM EDT
Completed Not applicable Interventional Results available

Cardiac Amyloidosis Discovery Trial

NCT06469372
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
Cardiac amyloidosis deep learning model
Device
Lead sponsor
Pierre Elias
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 21, 2026, 7:49 AM EDT
Not listed No phase listed Observational

Cardiac Amyloidosis Registry Study

NCT05174338
View directory record Official record
Conditions
Amyloidosis, Immunoglobulin Light-chain
Interventions
Registry
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • La Jolla, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 21, 2026, 7:49 AM EDT
Active, not recruiting No phase listed Observational

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

NCT07062848
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
AI Toolkit for ATTR-CM Diagnosis
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
50 Years to 95 Years
Enrollment
1,500,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Completed No phase listed Observational

Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

NCT02792790
View directory record Official record
Conditions
Amyloidosis, Cardiomyopathy, Transthyretin Amyloidosis, Senile Systemic Amyloidosis, Carpal Tunnel Syndrome
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 21, 2026, 7:49 AM EDT
Enrolling by invitation Phase 1 Interventional

PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis

NCT07771621
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
[18F]Fluselenamyl (FSA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Enrolling by invitation No phase listed Observational

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07398950
View directory record Official record
Conditions
ATTR Amyloidosis With Cardiomyopathy, Heart Failure
Interventions
ATTR-CM AI-ECG and AI-Echo Model
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 7:49 AM EDT
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 21, 2026, 7:49 AM EDT